{"nctId":"NCT00982644","briefTitle":"Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2009-09"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":1030,"armGroups":[{"label":"IDeg OD","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin glargine"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin glargine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus\n* Treatment with oral antidiabetic drugs (OADs) for at least three months before trial start at an unchanged dose\n* HbA1c: 7.0-10.0%\n* Body Mass Index (BMI) no higher than 40.0 kg/m\\^2\n* For the extension trial only: Completion of the 52 week treatment period in trial NN1250-3579 (NCT00982644)\n\nExclusion Criteria:\n\n* Treatment with exenatide or liraglutide within the last 3 months before trial start\n* Cardiovascular disease within the last 6 months\n* Uncontrolled treated/untreated severe hypertension\n* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures\n* Cancer and medical history of cancer","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment","description":"Change from baseline in HbA1c after 52 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.06","spread":"1.01"},{"groupId":"OG001","value":"-1.19","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"185","spread":null}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"172","spread":null},{"groupId":"OG001","value":"205","spread":null}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment","description":"Change from baseline in HbA1c after 104 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"1.04"},{"groupId":"OG001","value":"-1.11","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52","description":"Mean of 9-point SMPG at 52 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"1.8"},{"groupId":"OG001","value":"7.7","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Extension Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 104","description":"Mean of 9-point SMPG at 104 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"1.9"},{"groupId":"OG001","value":"7.6","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)","description":"Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"362","spread":null},{"groupId":"OG001","value":"339","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"254","spread":null},{"groupId":"OG001","value":"234","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":116,"n":766},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Back pain","Upper respiratory tract infection"]}}}